NETRF announces the appointment of Susan Payson as Chief Development Officer. In this new position, Susan will work to expand NETRF’s base of support to
by Laran Hyder, NETRF Associate Director of Development and Outreach As a NET patient or caregiver, living with neuroendocrine cancer can be an isolating experience.
The first step in curing a disease is understanding it. Unfortunately, there is a lot we still don’t know about small-intestinal NETs (SI-NETs). That’s why
by Ronny Allan, NET Patient Activist Doctors and scientists are always looking for better ways to care for patients with cancer; they are looking for
[breakout] Talk to your doctor before changing your activity level. You may need to make important modifications based on medication you are taking, surgery you
NETRF awarded six new research grants totaling $1.85 million to leading academic institutions around the world. The goal of the funding is to improve current treatments for neuroendocrine tumors (NETs), an uncommon and poorly understood cancer, which occurs in the body’s hormone-producing cells.
by Effie Tzameli, PhD, NETRF Director of Research The NETRF 2017 Request for Applications (RFA) was designed to invite innovative and transformative translational and clinical
A Journey in Advocacy Greta Stifel isn’t just “rare,” she’s triple “rare.” After being diagnosed with Carcinoid Cancer, she simultaneously developed Carcinoid Syndrome, and recently
New treatment for GI and pancreatic NETs The U.S. Food and Drug Administration (FDA) has approved Peptide Receptor Radionuclide Therapy (PRRT) with a new radiopharmaceutical for
World renown laboratory in the Netherlands to grown min-organs in Petri dishes to speed up NET drug testing.
